Celldex Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2012
Filed with the SEC on May 4, 2012 and accepted by EDGAR at May 4, 2012, 10:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-01-01 to 2012-03-31 | $2.4m | us-gaap:Revenues |
| Research and development | 3 months2012-01-01 to 2012-03-31 | $10.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2012-01-01 to 2012-03-31 | −$13.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-01-01 to 2012-03-31 | $433.0k | us-gaap:InterestExpense |
| Net income | 3 months2012-01-01 to 2012-03-31 | −$13.5m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2012-01-01 to 2012-03-31 | −$0.27 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2012-01-01 to 2012-03-31 | 50,145,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2012-01-01 to 2012-03-31 | −$13.6m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 3 months2012-01-01 to 2012-03-31 | $42.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-03-31 | $22.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-03-31 | $94.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2012-03-31 | $136.7m | us-gaap:Assets |
| Current liabilities | At period end2012-03-31 | $12.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-03-31 | $28.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-03-31 | $107.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-12-032960. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.